Ukr.Biochem.J. 2025; Volume 97, Issue 5, Sep-Oct, pp. 30-39

doi: https://doi.org/10.15407/ubj97.05.030

Protein mysterious structure and numerous functions department

10.11.2025   Uncategorized

V. O. Chernyshenko*, V. I. Gryshchuk

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine,
Department of Protein Structure and Function, Kyiv;
*e-mail: bio.cherv@gmail.com

Received: 02 July 2025; Revised: 30 July 2025;
Accepted: 30 October 2025; Available on-line: 02 December 2025

This overview is dedicated to the history of the Department of Protein Structure and Function at the Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine. It outlines the department’s main scientific objectives and highlights its key achievements. In particular, it describes research related to patient blood management, fundamental studies of fibrinogen structure and function, the development of next-generation antithrombotic prototypes, as well as the creation and clinical testing of diagnostic assays. Special attention is given to inventions and studies aimed at addressing pressing social issues, including post-traumatic stress disorder and the consequences of COVID-19. The importance of maintaining continuity in hemostasis research is emphasized, as it enables the generation of unique scientific results and their implementation in medical practice.

Keywords: , , , , , ,

References:

  1. Belitser VA, Tsybakova ET. On the mechanism of phosphorylation associated with respiration. Biochimia. 1939;4(5):516-535.
  2. Prebble JN. The discovery of oxidative phosphorylation: a conceptual off-shoot from the study of glycolysis. Stud Hist Philos Biol Biomed Sci. 2010;41(3):253-262. PubMed, CrossRef
  3. Mitchell P. Chemiosmotic Coupling: 1966. In Les Prix Nobel (The Nobel Prizes 1978), Editor Wilhelm Odelberg, [Nobel Foundation], Stockholm, 1979, р. 1-36.
  4. Belitser VA, Tsyperovich AS. Intermittency of denaturing conversion of protein molecule. Dokl Akad Nauk SSSR. 1952;83(2):257-259. PubMed
  5. Belitser VA, Varetskaja TV, Malneva GV. Fibrinogen-fibrin interaction. Biochim Biophys Acta. 1968;154(2):367-375. PubMed, CrossRef
  6. Varetskaya ТV. Microheterogeneity of fibrinogen. Cryofibrinogen. Ukr Biokhim Zhurn. 1960;32(1):13-24.
  7. Belitser VA, Varetska TV, Tsinkalovska SN. Estimation of the specific inhibitors of fibrin polymerization. Inhibitory units. Thromb Res. 1973;3: 251-264.
  8. Privalov PL, Medved LV. Domains in the fibrinogen molecule. J Mol Biol. 1982;159(4):665-683. PubMed, CrossRef
  9. Ugarova TP, Medved LV, Solovjov DA, Zolotukhin SV. USSR Patent No.: 1476649 titled “A method for preparation of clotting enzymes from the snake venom of Agkistrodon genus”. Registered 01/03/1989.
  10. Belitser VA. (Ed.) Protein Blood Substitute No. 8 (BK-8). Kyiv: Publishing House of the Academy of Sciences of the Ukrainian SSR, 1957. 242 p.
  11. Volkov GL, Havryliuk SP, Krasnobryzha YeM, Havryliuk OS, Zhukova AI. Method for isolating a complex of factor VIII and von Willebrand factor from other plasma proteins using size‑exclusion liquid chromatography. Patent of Ukraine No. 110920; published 10.03.2016 (Bulletin No. 05).
  12. Medved L, Weisel JW. The Story of the Fibrin(ogen) αC-Domains: Evolution of Our View on Their Structure and Interactions. Thromb Haemost. 2022;122(8):1265-1278. PubMed, PubMedCentral, CrossRef
  13. Belitser VA, Platonova TN, Pozdnyakova TM.Differences between the complexes formed by monomeric fibrin with fragment D and dimer D. Ukr Biokhim Zhurn. 1983;55(3):243-249. (In Ukrainian). PubMed
  14. Belitser VA, Varetskaya TV, Kosterin SA. Mechanism of inhibition of fibrin polymerization by fibrinogen and its active fragments. Biokhimiia. 1980;45(1):157-164. (In Russian). PubMed
  15. Ugarova TP, Kalikhevich VN, Ardemasova ZA, Belitser VA.The role of complementary E2 and D2 centers in the reaction between fibrin and fibrinogen. Biokhimiia. 1987;52(2):255-263. (In Russian). PubMed
  16. Pozdnyakova TM, Rybachuk VN, Ilyina AV, Davidovich IuA, Rogozhin SV. Effect of peptides – structural analogs of NH2-terminal sites of fibrin alpha- and beta-chains–on specific binding of the NH2-terminal disulfide bond of fibrin with fibrinogen. Ukr Biokhim Zhurn. 1986;58(2):10-15. (In Russia). PubMed
  17. Belitser VA, LugovskoyEV, Ugarova TP, Derzskaia SG. Interaction of fibrinogen with two forms of fibrin differing in the degree of activation by thrombin. Biokhimiia. 1985;50(8):1336-1341. (In Russian). PubMed
  18. Platonova T, Hrabovskyi O, Chernyshenko V, Stohnii Y, Kucheriavyi Y, Baidakova K, Korolova D, Urbanowicz A, Komisarenko S. Alternative Role of B/b Knob-Hole Interactions in the Fibrin Assembly. Biochemistry. 2025;64(4):791-800. PubMed, CrossRef
  19. Shatzel JJ, O’Donnell M, Olson SR, Kearney MR, Daughety MM, Hum J, Nguyen KP, DeLoughery TG. Venous thrombosis in unusual sites: A practical review for the hematologist. Eur J Haematol. 2019;102(1):53-62. PubMed, CrossRef
  20. O’Donnell M, Shatzel JJ, Olson SR, Daughety MM, Nguyen KP, Hum J, DeLoughery TG. Arterial thrombosis in unusual sites: A practical review. Eur J Haematol. 2018;101(6):728-736. PubMed, CrossRef
  21. Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood. 2013;121(10):1712-1719. PubMed, PubMedCentral, CrossRef
  22. Chernysh IN, Nagaswami C, Purohit PK, Weisel JW. Fibrin clots are equilibrium polymers that can be remodeled without proteolytic digestion. Sci Rep. 2012;2:879. PubMed, PubMedCentral, CrossRef
  23. Lugovskoy EV, Gritsenko PG, Kolesnikova IN, Lugovskaya NE, Komisarenko SV. A neoantigenic determinant in coiled coil region of human fibrin beta-chain. Thromb Res. 2009;123(5):765-770. PubMed, CrossRef
  24. Chernyshenko VO. Men of the molecules. Ukr Biochem J. 2020;92(3):86-90. CrossRef
  25. Pozniak TA, Urvant LP, Gritsenko PG, Chernishov VI, Pydiura NA, Lugovskoi EV, Komisarenko SV. Inhibition of fibrin polymerization by synthetic peptides corresponding to Аα195-205 and γ69-77 sites of fibrin molecule. Ukr Biochem J. 2014;86(4):119-125. CrossRef
  26. Lugovskoi E, Pydiura N, Makogonenko Y, Urvant L, Gritsenko P, Kolesnikova I, Lugovska N, Komisarenko S. The fibrin Bβ125-135 site is involved in the lateral association of protofibrils. Ukr Biochem J. 2020;92(3):33-45. CrossRef
  27. Komisarenko S, Chernyshenko V, Makogonenko Y, Pyrogova L, Lugovska N, Hornytska O, Hrabovskyi O. Patent of the invention. Method for inhibiting fibrin polymerization by synthetic peptides imitating fragments of the coiled-coil region of fibrin(ogen). Patent No. 143853. Application u202002124. Filed 30.03.2020. Published 29.12.2020.
  28. Komisarenko S, Chernyshenko V, Makogonenko Y, Pyrogova L, Lugovska N, Hornytska O, Hrabovskyi O. Method of inhibiting fibrin polymerization using synthetic peptides mimicking fragments of the coiled‑coil region of fibrin(ogen). International PCT‑application WO 2021/201813; filing date 29.03.2021; publication date 07.10.2021.
  29. Lugovskoy EV, Gritsenko PG, Koshel TA, Koliesnik IO, Cherenok SO, Kalchenko OI, Kalchenko VI, Komisarenko SV. Calix[4]arene methylenebisphosphonic acids as inhibitors of fibrin polymerization. FEBS J. 2011;278(8):1244-1251. PubMed, CrossRef
  30. Chernyshenko VO, Pirogova LV, Didkivskyi VA, Cherenok SO, Dosenko VE, Pashevin DO, Kalchenko VI, Makogonenko EM, Lugovskoy EV. Effects of calix[4]arene C-145 on overall haemostatic potential of blood plasma in vitro and in vivo. J Int Res Med Pharm Sci. 2016;10(3):146-151.
  31.  Chernyshenko VO, Savchuk OV, Cherenok SO, Silenko OM, Negelia AO, Kasatkina LO, Pirogova LV, Didkivskyi VA, Yusova OI, Kalchenko VI, Garmanchuk LV, Grinenko TV, Lugovskoy EV, Komisarenko SV. Haemostasis modulation by calix[4]arene methylenebisphosphonic acid C-145 and its sulfur-containing analogue. Ukr Biochem J. 2018;90(6):21-30. CrossRef
  32. Komisarenko S, Chernyshenko V, Didkivskyi V. Creation of a prototype drug “Antithrombotic agent calix[4]arene C-145” and its preclinical studies. In: National Academy of Sciences of Ukraine, editor. Kyiv: Publishing House “Akademperiodyka” NAS Ukraine; 2021. p. 19.
  33. Belitser VA. Fibrinogen B (soluble fibrinogen), its nature and methods of determination. Lab Delo. 1980:(9):529-532. (In Russian). PubMed
  34. Lugovskoy EV, Gritsenko PG, Lugovska NE, Kolesnikova IN, Komisarenko SV. Soluble fibrin: molecular structure and quantitative determination. Lab Diagnost. 2006;3(37):11-17.
  35. Lugovskoy EV, Kolesnikova IN, Gritsenko PG, Zolotareva EN, Gaffney P, Nieuwenhuizen W, Komisarenko SV. A neoantigenic determinant in the D-dimer fragment of fibrin. Thromb Res. 2002;107(3-4):151-156. PubMed, cr id=”https://doi.org/10.1016/s0049-3848(02)00204-9 “]
  36. Kolesnikova IN, Lugovska NE, Lugovskoy EV, Gritsenko PG, Lyashko KD, Gogolinska HK, Lytvynova LM, Kostyuchenko OP, Komisarenko SV. Monoclonal antibodies specific to human fibrin. Rep Nat Acad Sci Ukraine. 2006;(9):170-174.
  37. Komisarenko SV, Dieev VA, Lugovskoy EV et al. Methodical recommendations: “Application of immunoenzymatic methods for diagnosis of the risk of intravascular thrombosis.” Kyiv: Publisher Bykhun VYu, 2019. 36 p.
  38. Komisarenko SV, Korda MM, Vari SH, Chernyshenko VO, et al. Determination of the risk of intravascular thrombosis in patients recovered from COVID-19: Methodical recommendations. Ternopil: TNMU; 2024. 40 p.
  39. Burg MM, Edmondson D, Shimbo D, Shaffer J, Kronish IM, Whang W, Alcántara C, Schwartz JE, Muntner P, Davidson KW. The ‘perfect storm’ and acute coronary syndrome onset: do psychosocial factors play a role? Prog Cardiovasc Dis. 2013;55(6):601-610. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.